KURA ONCOLOGY INC's ticker is KURA and the CUSIP is 50127T109. A total of 142 filers reported holding KURA ONCOLOGY INC in Q4 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $377 | +16.4% | 41,309 | +34.9% | 0.00% | +33.3% |
| Q2 2023 | $324 | -77.4% | 30,624 | -73.9% | 0.00% | -75.0% |
| Q1 2023 | $1,436 | +39.3% | 117,434 | +41.4% | 0.01% | -20.0% |
| Q4 2022 | $1,031 | -99.9% | 83,040 | -34.0% | 0.02% | -31.8% |
| Q3 2022 | $1,718,000 | +79.1% | 125,749 | +140.3% | 0.02% | +83.3% |
| Q2 2022 | $959,000 | +217.5% | 52,330 | +178.5% | 0.01% | +200.0% |
| Q1 2022 | $302,000 | -17.7% | 18,790 | -4.0% | 0.00% | -20.0% |
| Q3 2021 | $367,000 | +68.3% | 19,581 | +87.0% | 0.01% | +150.0% |
| Q2 2021 | $218,000 | -60.4% | 10,472 | -37.9% | 0.00% | -60.0% |
| Q4 2020 | $551,000 | -35.4% | 16,868 | -39.4% | 0.01% | -70.6% |
| Q3 2020 | $853,000 | +173.4% | 27,843 | +45.3% | 0.02% | +112.5% |
| Q2 2020 | $312,000 | +110.8% | 19,169 | +77.9% | 0.01% | +166.7% |
| Q4 2019 | $148,000 | – | 10,773 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,849,947 | $16,871,517 | 9.37% |
| Prosight Management, LP | 1,932,456 | $17,623,999 | 5.58% |
| ACUTA CAPITAL PARTNERS, LLC | 702,093 | $6,403,088 | 4.29% |
| ALETHEA CAPITAL MANAGEMENT, LLC | 350,445 | $3,196,058 | 3.93% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,335,845 | $66,902,906 | 3.62% |
| Affinity Asset Advisors, LLC | 856,535 | $7,811,599 | 2.20% |
| TCG Crossover Management, LLC | 1,423,642 | $12,983,615 | 1.91% |
| EcoR1 Capital, LLC | 5,806,871 | $52,958,664 | 1.79% |
| BVF INC/IL | 6,730,983 | $61,386,565 | 1.66% |
| DAFNA Capital Management LLC | 550,784 | $5,023,150 | 1.56% |